10 Key Variables driving HealthTech and MedTech M&A valuation multiples throughout 2025

Across 2025, HealthTech and MedTech M&A multiples have clustered around x4 to x6 revenue for most assets, with clear premiums where specific strategic and financial variables line up.​

Company quality and financial profile

Stage, size and profitability – Later‑stage, scaled assets with positive EBITDA and >£20–30m revenue command higher revenue and EBITDA multiples than early‑stage or sub‑scale startups, which often compress to 3–4x unless strategically unique.​

Revenue growth and visibility – Sustained organic growth >25–30% with contracted or recurring components (SaaS, subscription, consumables) supports upper‑quartile valuations; flat or volatile revenue pushes deals toward the lower end of the range.​

Margin structure and unit economics – High gross margins (70%+ for software / digital; >60% for premium MedTech) and attractive LTV/CAC or payback periods justify premium pricing versus hardware‑heavy or low‑margin, labour‑intensive models.​

Strategic fit, differentiation and risk

IP, clinical evidence and “technology moat” – Proprietary algorithms, protected devices or clinically validated platforms (e.g. RCTs, real‑world outcomes, reimbursement codes) underpin defensibility and can lift valuations into 6–8x+ revenue for top assets.​

Regulatory position and market access – Clean MDR / IVDR or FDA status, clear SaMD classification, and established reimbursement (e.g. procedure codes, DiGA‑style listing, HTA support) reduce execution risk and support higher multiples than assets still pre‑clearance.​

Alignment with value‑based care and system priorities – Solutions that demonstrably reduce cost or improve outcomes in priority areas (chronic disease, hospital at home, productivity, workforce shortages) attract strategic buyers and 5.5–7x+ revenue ranges.​

Sector and macro positioning

Exposure to AI, data and infrastructure – AI‑first diagnostics, workflow automation, and data or infrastructure plays (EHDS‑aligned, interoperability, RCM, analytics) are repeatedly cited as earning the highest HealthTech and MedTech premiums in 2025.​

Sub‑sector and demand tailwinds – Segments like value‑based care platforms, telehealth, robotics, advanced imaging, and minimally invasive devices benefit from ageing populations and chronic disease trends, sustaining 6–8x+ revenue for best‑in‑class companies.​

Deal dynamics and capital markets

Buyer universe and competitive tension – Multiples spike where there is strong interest from both strategics and PE with “dry powder”, especially in auction processes for scarce assets; bilateral or distressed situations clear at discounts.​

Funding environment, rates and exit options – Higher interest rates, tariff and policy uncertainty, and IPO market weakness have kept many 2025 deals disciplined, but easing rates and clearer EU AI/EHDS rules are starting to stabilise or lift MedTech and digital‑health valuations in H2 2025.

To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email [email protected]